Prime Medicine (NASDAQ:PRME - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 87.35% from the stock's current price.
PRME has been the subject of several other reports. Jefferies Financial Group reiterated a "market outperform" rating on shares of Prime Medicine in a research report on Monday, September 28th. BMO Capital Markets started coverage on Prime Medicine in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $9.00 target price on the stock. Citigroup restated a "market outperform" rating on shares of Prime Medicine in a research report on Friday, September 25th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Prime Medicine in a research note on Monday, August 31st. Finally, Wall Street Zen upgraded Prime Medicine from a "sell" rating to a "hold" rating in a report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $7.86.
Check Out Our Latest Stock Analysis on PRME
Prime Medicine Price Performance
Prime Medicine stock opened at $4.27 on Monday. The firm has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $3.51. Prime Medicine has a 1-year low of $2.67 and a 1-year high of $5.91. The stock has a market cap of $774.49 million, a price-to-earnings ratio of -4.45 and a beta of 2.13.
Prime Medicine (NASDAQ:PRME - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $4.21 million during the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. Equities analysts expect that Prime Medicine will post -0.97 earnings per share for the current fiscal year.
Institutional Trading of Prime Medicine
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRME. Marshall Wace LLP lifted its stake in Prime Medicine by 225.7% during the third quarter. Marshall Wace LLP now owns 706,281 shares of the company's stock worth $2,161,000 after purchasing an additional 489,440 shares in the last quarter. Empowered Funds LLC purchased a new position in shares of Prime Medicine during the third quarter worth $150,000. Palumbo Wealth Management LLC boosted its position in shares of Prime Medicine by 52.2% during the third quarter. Palumbo Wealth Management LLC now owns 157,962 shares of the company's stock worth $483,000 after buying an additional 54,161 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Prime Medicine by 244.2% in the third quarter. Russell Investments Group Ltd. now owns 175,500 shares of the company's stock valued at $536,000 after buying an additional 124,506 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. acquired a new stake in shares of Prime Medicine in the third quarter valued at $350,000. Hedge funds and other institutional investors own 70.37% of the company's stock.
About Prime Medicine
(
Get Free Report)
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prime Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.
While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.